おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
I-Mab Biopharma
company
About
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $220M
- Industries
- Biotechnology,Pharmaceutical,Product Research
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$220M
I-Mab Biopharma has raised a total of
$220M
in funding over 2 rounds. Their latest funding was raised on
Jun 29, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 29, 2018 | Series C | $220M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
I-Mab Biopharma is funded by 2 investors.
Tally Capital
and HOPU Investment Management Company
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Tally Capital
|
— | Series C |
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
